{"id":"amiloride","rwe":[],"_fda":{"id":"84adc61b-3ed3-452d-a1b8-d062869b263d","set_id":"18d551a9-ffc7-4b14-adbd-92d84aa8e966","openfda":{"unii":["7M458Q65S3"],"route":["ORAL"],"rxcui":["977880"],"spl_id":["84adc61b-3ed3-452d-a1b8-d062869b263d"],"brand_name":["Amiloride Hydrochloride"],"spl_set_id":["18d551a9-ffc7-4b14-adbd-92d84aa8e966"],"package_ndc":["63629-2114-1"],"product_ndc":["63629-2114"],"generic_name":["AMILORIDE HYDROCHLORIDE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["AMILORIDE HYDROCHLORIDE ANHYDROUS"],"manufacturer_name":["Bryant Ranch Prepack"],"application_number":["ANDA070346"],"original_packager_product_ndc":["49884-117"]},"version":"103","warnings":["WARNINGS Hyperkalemia Like other potassium-conserving agents, amiloride may cause hyperkalemia (serum potassium levels greater than 5.5 mEq per liter) which, if uncorrected, is potentially fatal. Hyperkalemia occurs commonly (about 10%) when amiloride is used without a kaliuretic diuretic. This incidence is greater in patients with renal impairment, diabetes mellitus (with or without recognized renal insufficiency), and in the elderly. When amiloride is used concomitantly with a thiazide diuretic in patients without these complications, the risk of hyperkalemia is reduced to about 1-2%. It is thus essential to monitor serum potassium levels carefully in any patient receiving amiloride, particularly when it is first introduced, at the time of diuretic dosage adjustments, and during any illness that could affect renal function. The risk of hyperkalemia may be increased when potassium-conserving agents, including amiloride HCl, are administered concomitantly with an angiotensin-converting enzyme inhibitor, an angiotensin II receptor antagonist, cyclosporine or tacrolimus. (See PRECAUTIONS , Drug Interactions. ) Warning signs or symptoms of hyperkalemia include paresthesias, muscular weakness, fatigue, flaccid paralysis of the extremities, bradycardia, shock, and ECG abnormalities. Monitoring of the serum potassium level is essential because mild hyperkalemia is not usually associated with an abnormal ECG. When abnormal, the ECG in hyperkalemia is characterized primarily by tall, peaked T waves or elevations from previous tracings. There may also be lowering of the R wave and increased depth of the S wave, widening and even disappearance of the P wave, progressive widening of the QRS complex, prolongation of the PR interval, and ST depression. Treatment of hyperkalemia: If hyperkalemia occurs in patients taking amiloride HCl, the drug should be discontinued immediately. If the serum potassium level exceeds 6.5 mEq per liter, active measures should be taken to reduce it. Such measures include the intravenous administration of sodium bicarbonate solution or oral or parenteral glucose with a rapid-acting insulin preparation. If needed, a cation exchange resin such as sodium polystyrene sulfonate may be given orally or by enema. Patients with persistent hyperkalemia may require dialysis. Diabetes Mellitus In diabetic patients, hyperkalemia has been reported with the use of all potassium-conserving diuretics, including amiloride HCl, even in patients without evidence of diabetic nephropathy. Therefore, amiloride HCl should be avoided, if possible, in diabetic patients and, if it is used, serum electrolytes and renal function must be monitored frequently. Amiloride HCl should be discontinued at least 3 days before glucose tolerance testing. Metabolic or Respiratory Acidosis Antikaliuretic therapy should be instituted only with caution in severely ill patients in whom respiratory or metabolic acidosis may occur, such as patients with cardiopulmonary disease or poorly controlled diabetes. If amiloride HCl is given to these patients, frequent monitoring of acid-base balance is necessary. Shifts in acid-base balance alter the ratio of extracellular/intracellular potassium, and the development of acidosis may be associated with rapid increases in serum potassium levels."],"pregnancy":["Pregnancy Pregnancy Category B . Teratogenicity studies with amiloride HCl in rabbits and mice given 20 and 25 times the maximum human dose, respectively, revealed no evidence of harm to the fetus, although studies showed that the drug crossed the placenta in modest amounts. Reproduction studies in rats at 20 times the expected maximum daily dose for humans showed no evidence of impaired fertility. At approximately 5 or more times the expected maximum daily dose for humans, some toxicity was seen in adult rats and rabbits and a decrease in rat pup growth and survival occurred. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed."],"overdosage":["OVERDOSAGE No data are available in regard to overdosage in humans. The oral LD 50 of amiloride HCl (calculated as the base) is 56 mg/kg in mice and 36 to 85 mg/kg in rats, depending on the strain. It is not known whether the drug is dialyzable. The most likely signs and symptoms to be expected with overdosage are dehydration and electrolyte imbalance. These can be treated by established procedures. Therapy with amiloride HCl should be discontinued and the patient observed closely. There is no specific antidote.Emesis should be induced or gastric lavage performed.Treatment is symptomatic and supportive. If hyperkalemia occurs, active measures should be taken to reduce the serum potassium levels."],"description":["DESCRIPTION Amiloride HCl, an antikaliuretic-diuretic agent, is a pyrazine-carbonyl-guanidine that is unrelated chemically to other known antikaliuretic or diuretic agents. It is the salt of a moderately strong base (pKa 8.7). It is designated chemically as 3,5-diamino-6-chloro-N-(diaminomethylene) pyrazinecarboxamide monohydrochloride, dihydrate and has a molecular weight of 302.12. Its empirical formula is C 6 H 8 CIN 7 O•HCl•2H 2 O and its structural formula is: Each tablet for oral administration contains 5 mg of Amiloride HCI, calculated on the anhydrous basis. Each tablet contains the following inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, D&C yellow #10 lake, dibasic calcium phosphate dihydrate, FD&C yellow #6 lake, magnesium stearate, microcrystalline cellulose and silicon dioxide."],"precautions":["GENERAL PRECAUTIONS Electrolyte Imbalance and BUN Increases Hyponatremia and hypochloremia may occur when amiloride HCl is used with other diuretics and increases in BUN levels have been reported. These increases usually have accompanied vigorous fluid elimination, especially when diuretic therapy was used in seriously ill patients, such as those who had hepatic cirrhosis with ascites and metabolic alkalosis, or those with resistant edema. Therefore, when amiloride HCl is given with other diuretics to such patients, careful monitoring of serum electrolytes and BUN levels is important. In patients with pre-existing severe liver disease, hepatic encephalopathy, manifested by tremors, confusion, and coma, and increased jaundice, have been reported in association with diuretics, including amiloride HCl. Drug Interactions When amiloride HCl is administered concomitantly with an angiotensin-converting enzyme inhibitor, an angiotensin II receptor antagonist, cyclosporine or tacrolimus, the risk of hyperkalemia may be increased. Therefore, if concomitant use of these agents is indicated because of demonstrated hypokalemia, they should be used with caution and with frequent monitoring of serum potassium. (See WARNINGS ). Lithium generally should not be given with diuretics because they reduce its renal clearance and add a high risk of lithium toxicity. Read circulars for lithium preparations before use of such concomitant therapy. In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. Therefore, when amiloride HCl and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained. Since indomethacin and potassium-sparing diuretics, including amiloride HCl, may each be associated with increased serum potassium levels, the potential effects on potassium kinetics and renal function should be considered when these agents are administered concurrently. Carcinogenesis and Mutagenesis and Impairment of Fertility There was no evidence of a tumorigenic effect when amiloride HCl was administered for 92 weeks to mice at doses up to 10 mg/kg/day (25 times the maximum daily human dose). Amiloride HCl has also been administered for 104 weeks to male and female rats at doses up to 6 and 8 mg/kg/day (15 and 20 times the maximum daily dose for humans, respectively) and showed no evidence of carcinogenicity. Amiloride HCl was devoid of mutagenic activity in various strains of Salmonella typhimurium with or without a mammalian liver microsomal activation system (Ames test). Pregnancy Pregnancy Category B . Teratogenicity studies with amiloride HCl in rabbits and mice given 20 and 25 times the maximum human dose, respectively, revealed no evidence of harm to the fetus, although studies showed that the drug crossed the placenta in modest amounts. Reproduction studies in rats at 20 times the expected maximum daily dose for humans showed no evidence of impaired fertility. At approximately 5 or more times the expected maximum daily dose for humans, some toxicity was seen in adult rats and rabbits and a decrease in rat pup growth and survival occurred. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. Nursing Mothers Studies in rats have shown that amiloride is excreted in milk in concentrations higher than those found in blood, but it is not known whether amiloride is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from amiloride HCl, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. Pediatric Use Safety and effectiveness in pediatric patients have not been established. Geriatric Use Clinical studies of amiloride HCI did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy. This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. (See CONTRAINDICATIONS , Impaired Renal Function. )"],"how_supplied":["HOW SUPPLIED Each yellow compressed tablet contains 5 mg of anhydrous Amiloride HCl and is debossed “Par 117”. Store at controlled room temperature 15°-30°C (59°-86°F). Dispense in a tight, light-resistant container as defined in the USP. Repackaged/Relabeled by: Bryant Ranch Prepack, Inc. Burbank, CA 91504"],"geriatric_use":["Geriatric Use Clinical studies of amiloride HCI did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy. This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. (See CONTRAINDICATIONS , Impaired Renal Function. )"],"pediatric_use":["Pediatric Use Safety and effectiveness in pediatric patients have not been established."],"effective_time":"20231128","nursing_mothers":["Nursing Mothers Studies in rats have shown that amiloride is excreted in milk in concentrations higher than those found in blood, but it is not known whether amiloride is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from amiloride HCl, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother."],"adverse_reactions":["ADVERSE REACTIONS Amiloride HCl is usually well tolerated and, except for hyperkalemia (serum potassium levels greater than 5.5 mEq liter - see WARNINGS), significant adverse effects have been reported infrequently. Minor adverse reactions were reported relatively frequently (about 20%) but the relationship of many of the reports to amiloride HCl is uncertain and the overall frequency was similar in hydrochlorothiazide treated groups. Nausea/anorexia, abdominal pain, flatulence, and mild skin rash have been reported and probably are related to amiloride. Other adverse experiences that have been reported with amiloride are generally those known to be associated with diuresis, or with the underlying disease being treated. The adverse reactions for amiloride HCl listed in the following table have been arranged into two groups: (1) incidence greater than one percent; and (2) incidence one percent or less. The incidence for group (1) was determined from clinical studies conducted in the United States (837 patients treated with amiloride HCl). The adverse effects listed in group (2) include reports from the same clinical studies and voluntary reports since marketing. The probability of a causal relationship exists between amiloride HCl and these adverse reactions, some of which have been reported only rarely. *Reactions occurring in 3% to 8% of patients treated with amiloride HCl. (Those reactions occurring in less than 3% of the patients are unmarked.) **See WARNINGS. Incidence > 1% Incidence ≤ 1% Body as a Whole Headache* Back pain Weakness Chest pain Fatigability Neck/shoulder ache Pain, extremities Cardiovascular None Angina pectoris Orthostatic hypotension Arrhythmia Palpitation Digestive Nausea/anorexia* Jaundice Diarrhea* GI bleeding Vomiting* Abdominal fullness Abdominal pain GI disturbance Gas pain Thirst Appetite changes Heartburn Constipation Flatulence Dyspepsia Metabolic Elevated serum potassium levels (>5.5 mEq per liter)** None Skin None Skin rash Itching Dryness of mouth Pruritus Alopecia Musculoskeletal Muscle cramps Joint pain Leg ache Nervous Dizziness Paresthesia Encephalopathy Tremors Vertigo Psychiatric None Nervousness Mental confusion Insomnia Decreased libido Depression Somnolence Respiratory Cough Shortness of Breath Dyspnea Special Senses None Visual disturbances Nasal congestion Tinnitus Increased intraocular pressure Urogenital Impotence Polyuria Dysuria Urinary frequency Bladder spasms Gynecomastia Causal Relationship Unknown Other reactions have been reported but occurred under circumstances where a causal relationship could not be established. However, in these rarely reported events, that possibility cannot be excluded. Therefore, these observations are listed to serve as alerting information to physicians. Activation of probable pre-existing peptic ulcer Aplastic anemia Neutropenia Abnormal liver function"],"contraindications":["CONTRAINDICATIONS Hyperkalemia Amiloride HCl should not be used in the presence of elevated serum potassium levels (greater than 5.5 mEq per liter). Antikaliuretic Therapy or Potassium Supplementation Amiloride HCl should not be given to patients receiving other potassium-conserving agents, such as spironolactone or triamterene. Potassium supplementation in the form of medication, potassium-containing salt substitutes or a potassium-rich diet should not be used with amiloride HCl except in severe and/or refractory cases of hypokalemia. Such concomitant therapy can be associated with rapid increases in serum potassium levels. If potassium supplementation is used, careful monitoring of the serum potassium level is necessary. Impaired Renal Function Anuria, acute or chronic renal insufficiency, and evidence of diabetic nephropathy are contraindications to the use of amiloride HCl. Patients with evidence of renal functional impairment (blood urea nitrogen [BUN] levels over 30 mg per 100 mL or serum creatinine levels over 1.5 mg per 100 mL) or diabetes mellitus should not receive the drug without careful, frequent and continuing monitoring of serum electrolytes, creatinine, and BUN levels. Potassium retention associated with the use of an antikaliuretic agent is accentuated in the presence of renal impairment and may result in the rapid development of hyperkalemia. Hypersensitivity Amiloride HCl is contraindicated in patients who are hypersensitive to this product."],"drug_interactions":["Drug Interactions When amiloride HCl is administered concomitantly with an angiotensin-converting enzyme inhibitor, an angiotensin II receptor antagonist, cyclosporine or tacrolimus, the risk of hyperkalemia may be increased. Therefore, if concomitant use of these agents is indicated because of demonstrated hypokalemia, they should be used with caution and with frequent monitoring of serum potassium. (See WARNINGS ). Lithium generally should not be given with diuretics because they reduce its renal clearance and add a high risk of lithium toxicity. Read circulars for lithium preparations before use of such concomitant therapy. In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. Therefore, when amiloride HCl and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained. Since indomethacin and potassium-sparing diuretics, including amiloride HCl, may each be associated with increased serum potassium levels, the potential effects on potassium kinetics and renal function should be considered when these agents are administered concurrently."],"clinical_pharmacology":["CLINICAL PHARMACOLOGY Amiloride HCl is a potassium-conserving (antikaliuretic) drug that possesses weak (compared with thiazide diuretics) natriuretic, diuretic, and antihypertensive activity. These effects have been partially additive to the effects of thiazide diuretics in some clinical studies. When administered with a thiazide or loop diuretic, amiloride has been shown to decrease the enhanced urinary excretion of magnesium which occurs when a thiazide or loop diuretic is used alone. Amiloride has potassium-conserving activity in patients receiving kaliureticdiuretic agents. Amiloride HCl is not an aldosterone antagonist and its effects are seen even in the absence of aldosterone. Amiloride exerts its potassium sparing effect through the inhibition of sodium reabsorption at the distal convoluted tubule, cortical collecting tubule and collecting duct; this decreases the net negative potential of the tubular lumen and reduces both potassium and hydrogen secretion and their subsequent excretion. This mechanism accounts in large part for the potassium sparing action of amiloride. Amiloride usually begins to act within 2 hours after an oral dose. Its effect on electrolyte excretion reaches a peak between 6 and 10 hours and lasts about 24 hours. Peak plasma levels are obtained in 3 to 4 hours and the plasma half-life varies from 6 to 9 hours. Effects on electrolytes increase with single doses of amiloride HCl up to approximately 15 mg. Amiloride HCl is not metabolized by the liver but is excreted unchanged by the kidneys. About 50 percent of a 20 mg dose of amiloride HCl is excreted in the urine and 40 percent in the stool within 72 hours. Amiloride has little effect on glomerular filtration rate or renal blood flow. Because amiloride HCl is not metabolized by the liver, drug accumulation is not anticipated in patients with hepatic dysfunction, but accumulation can occur if the hepatorenal syndrome develops."],"indications_and_usage":["INDICATIONS AND USAGE Amiloride HCl is indicated as adjunctive treatment with thiazide diuretics or other kaliureticdiuretic agents in congestive heart failure or hypertension to: help restore normal serum potassium levels in patients who develop hypokalemia on the kaliuretic diuretic. prevent development of hypokalemia in patients who would be exposed to particular risk if hypokalemia were to develop, e.g., digitalized patients or patients with significant cardiac arrhythmias. The use of potassium-conserving agents is often unnecessary in patients receiving diuretics for uncomplicated essential hypertension when such patients have a normal diet. Amiloride HCl has little additive diuretic or antihypertensive effect when added to a thiazide diuretic. Amiloride HCl should rarely be used alone. It has weak (compared with thiazides) diuretic and antihypertensive effects. Used as single agents, potassium sparing diuretics, including amiloride HCl, result in an increased risk of hyperkalemia (approximately 10% with amiloride). Amiloride HCl should be used alone only when persistent hypokalemia has been documented and only with careful titration of the dose and close monitoring of serum electrolytes."],"adverse_reactions_table":["
*Reactions occurring in 3% to 8% of patients treated with amiloride HCl.
(Those reactions occurring in less than 3% of the patients are unmarked.)
**See WARNINGS.
Incidence > 1%Incidence ≤ 1%
Body as a Whole
Headache* Back pain
Weakness Chest pain
Fatigability Neck/shoulder ache
Pain, extremities
Cardiovascular
None Angina pectoris
Orthostatic hypotension
Arrhythmia
Palpitation
Digestive
Nausea/anorexia* Jaundice
Diarrhea* GI bleeding
Vomiting* Abdominal fullness
Abdominal pain GI disturbance
Gas pain Thirst
Appetite changes Heartburn
Constipation Flatulence
Dyspepsia
Metabolic Elevated serum potassium levels (>5.5 mEq per liter)** None
Skin
None Skin rash
Itching
Dryness of mouth
Pruritus
Alopecia
Musculoskeletal
Muscle cramps Joint pain
Leg ache
Nervous
Dizziness Paresthesia
Encephalopathy Tremors
Vertigo
Psychiatric
None Nervousness
Mental confusion
Insomnia
Decreased libido
Depression
Somnolence
Respiratory
Cough Shortness of Breath
Dyspnea
Special Senses
None Visual disturbances
Nasal congestion
Tinnitus
Increased intraocular pressure
Urogenital
Impotence Polyuria
Dysuria
Urinary frequency
Bladder spasms
Gynecomastia
"],"dosage_and_administration":["DOSAGE AND ADMINISTRATION Amiloride HCl should be administered with food. Amiloride HCl, one 5 mg tablet daily, should be added to the usual antihypertensive or diuretic dosage of a kaliuretic diuretic. The dosage may be increased to 10 mg per day, if necessary. More than two 5 mg tablets of amiloride HCl daily usually are not needed, and there is little controlled experience with such doses. If persistent hypokalemia is documented with 10 mg, the dose can be increased to 15 mg, then 20 mg, with careful monitoring of electrolytes. In treating patients with congestive heart failure after an initial diuresis has been achieved, potassium loss may also decrease and the need for amiloride HCl should be re-evaluated. Dosage adjustment may be necessary. Maintenance therapy may be on an intermittent basis. If it is necessary to use amiloride HCl alone (see INDICATIONS), the starting dosage should be one 5 mg tablet daily. This dosage may be increased to 10 mg per day, if necessary. More than two 5 mg tablets usually are not needed, and there is little controlled experience with such doses. If persistent hypokalemia is documented with 10 mg, the dose can be increased to 15 mg, then 20 mg, with careful monitoring of electrolytes."],"spl_product_data_elements":["Amiloride Hydrochloride Amiloride Hydrochloride AMILORIDE HYDROCHLORIDE ANHYDROUS AMILORIDE D&C YELLOW NO. 10 FD&C YELLOW NO. 6 DIBASIC CALCIUM PHOSPHATE DIHYDRATE MAGNESIUM STEARATE MICROCRYSTALLINE CELLULOSE SILICON DIOXIDE Par;117 this is the structure."],"package_label_principal_display_panel":["Amiloride Hcl Anhydrous 5 mg Tab, #1000 Label"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["Carcinogenesis and Mutagenesis and Impairment of Fertility There was no evidence of a tumorigenic effect when amiloride HCl was administered for 92 weeks to mice at doses up to 10 mg/kg/day (25 times the maximum daily human dose). Amiloride HCl has also been administered for 104 weeks to male and female rats at doses up to 6 and 8 mg/kg/day (15 and 20 times the maximum daily dose for humans, respectively) and showed no evidence of carcinogenicity. Amiloride HCl was devoid of mutagenic activity in various strains of Salmonella typhimurium with or without a mammalian liver microsomal activation system (Ames test)."]},"tags":[{"label":"Potassium-sparing Diuretic","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Amiloride-sensitive sodium channel, ENaC","category":"target"},{"label":"SCNN1A","category":"gene"},{"label":"SCNN1B","category":"gene"},{"label":"SCNN1G","category":"gene"},{"label":"C03DB01","category":"atc"},{"label":"Oral","category":"route"},{"label":"Tablet","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Mature","category":"status"},{"label":"Edema","category":"indication"},{"label":"Hypertensive disorder","category":"indication"},{"label":"Hypokalemia Prevention","category":"indication"},{"label":"Padagis Us","category":"company"},{"label":"Approved 1980s","category":"decade"},{"label":"Acid Sensing Ion Channel Blockers","category":"pharmacology"},{"label":"Diuretics","category":"pharmacology"},{"label":"Epithelial Sodium Channel Blockers","category":"pharmacology"},{"label":"Membrane Transport Modulators","category":"pharmacology"},{"label":"Natriuretic Agents","category":"pharmacology"},{"label":"Sodium Channel Blockers","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"DYSPNOEA","source":"FDA FAERS","actionTaken":"72 reports"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"63 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"54 reports"},{"date":"","signal":"VOMITING","source":"FDA FAERS","actionTaken":"46 reports"},{"date":"","signal":"FALL","source":"FDA FAERS","actionTaken":"39 reports"},{"date":"","signal":"MALAISE","source":"FDA FAERS","actionTaken":"38 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"37 reports"},{"date":"","signal":"CONFUSIONAL STATE","source":"FDA FAERS","actionTaken":"35 reports"},{"date":"","signal":"DRUG INTERACTION","source":"FDA FAERS","actionTaken":"35 reports"},{"date":"","signal":"HEADACHE","source":"FDA FAERS","actionTaken":"33 reports"}],"drugInteractions":[{"url":"/drug/benazepril","drug":"benazepril","action":"Monitor closely","effect":"May interact with Benazepril","source":"DrugCentral","drugSlug":"benazepril"},{"url":"/drug/captopril","drug":"captopril","action":"Monitor closely","effect":"May interact with Captopril","source":"DrugCentral","drugSlug":"captopril"},{"url":"/drug/enalapril","drug":"enalapril","action":"Monitor closely","effect":"May interact with Enalapril","source":"DrugCentral","drugSlug":"enalapril"},{"url":"/drug/eprosartan","drug":"eprosartan","action":"Monitor closely","effect":"May interact with Eprosartan","source":"DrugCentral","drugSlug":"eprosartan"},{"url":"/drug/fosinopril","drug":"fosinopril","action":"Monitor closely","effect":"May interact with Fosinopril","source":"DrugCentral","drugSlug":"fosinopril"},{"url":"/drug/irbesartan","drug":"irbesartan","action":"Monitor closely","effect":"May interact with Irbesartan","source":"DrugCentral","drugSlug":"irbesartan"},{"url":"/drug/lisinopril","drug":"lisinopril","action":"Monitor closely","effect":"May interact with Lisinopril","source":"DrugCentral","drugSlug":"lisinopril"},{"url":"/drug/losartan","drug":"losartan","action":"Monitor closely","effect":"May interact with Losartan","source":"DrugCentral","drugSlug":"losartan"},{"url":"/drug/perindopril","drug":"perindopril","action":"Monitor closely","effect":"May interact with Perindopril","source":"DrugCentral","drugSlug":"perindopril"},{"url":"/drug/potassium-acetate","drug":"potassium acetate","action":"Monitor closely","effect":"May interact with Potassium Acetate","source":"DrugCentral","drugSlug":"potassium-acetate"},{"url":"/drug/potassium-chloride","drug":"potassium chloride","action":"Monitor closely","effect":"May interact with Potassium Chloride","source":"DrugCentral","drugSlug":"potassium-chloride"},{"url":"/drug/potassium-citrate","drug":"potassium citrate","action":"Monitor closely","effect":"May interact with Potassium Citrate","source":"DrugCentral","drugSlug":"potassium-citrate"},{"url":"/drug/potassium-gluconate","drug":"potassium gluconate","action":"Monitor closely","effect":"May interact with Potassium Gluconate","source":"DrugCentral","drugSlug":"potassium-gluconate"},{"url":"/drug/potassium-hydrogencarbonate","drug":"potassium hydrogencarbonate","action":"Monitor closely","effect":"May interact with Potassium Bicarbonate","source":"DrugCentral","drugSlug":"potassium-hydrogencarbonate"},{"url":"/drug/potassium-iodide","drug":"potassium iodide","action":"Monitor closely","effect":"May interact with Potassium Iodide","source":"DrugCentral","drugSlug":"potassium-iodide"},{"url":"/drug/potassium-phosphate","drug":"potassium phosphate","action":"Monitor closely","effect":"May interact with Potassium Phosphate","source":"DrugCentral","drugSlug":"potassium-phosphate"},{"url":"/drug/quinapril","drug":"quinapril","action":"Monitor closely","effect":"May interact with Quinapril","source":"DrugCentral","drugSlug":"quinapril"},{"url":"/drug/quinidine","drug":"quinidine","action":"Monitor closely","effect":"May interact with Quinidine","source":"DrugCentral","drugSlug":"quinidine"},{"url":"/drug/ramipril","drug":"ramipril","action":"Monitor closely","effect":"May interact with Ramipril","source":"DrugCentral","drugSlug":"ramipril"},{"url":"/drug/telmisartan","drug":"telmisartan","action":"Monitor closely","effect":"May interact with Telmisartan","source":"DrugCentral","drugSlug":"telmisartan"}],"commonSideEffects":[{"effect":"Headache","drugRate":"1%","severity":"common","_validated":true},{"effect":"Back pain","drugRate":"1%","severity":"common","_validated":true},{"effect":"Weakness","drugRate":"1%","severity":"common","_validated":true},{"effect":"Chest pain","drugRate":"1%","severity":"common","_validated":true},{"effect":"Fatigability","drugRate":"1%","severity":"common","_validated":true},{"effect":"Neck/shoulder ache","drugRate":"1%","severity":"common","_validated":true},{"effect":"Pain, extremities","drugRate":"1%","severity":"common","_validated":true},{"effect":"Nausea/anorexia","drugRate":"reported","severity":"common"},{"effect":"Jaundice","drugRate":"reported","severity":"serious"},{"effect":"Diarrhea","drugRate":"reported","severity":"common"},{"effect":"GI bleeding","drugRate":"reported","severity":"serious"},{"effect":"Vomiting","drugRate":"reported","severity":"common"},{"effect":"Abdominal fullness","drugRate":"reported","severity":"mild"},{"effect":"Abdominal pain","drugRate":"reported","severity":"common"},{"effect":"GI disturbance","drugRate":"reported","severity":"mild"},{"effect":"Gas pain","drugRate":"reported","severity":"mild"},{"effect":"Thirst","drugRate":"reported","severity":"mild"},{"effect":"Appetite changes","drugRate":"reported","severity":"mild"},{"effect":"Heartburn","drugRate":"reported","severity":"mild"},{"effect":"Constipation","drugRate":"reported","severity":"mild"},{"effect":"Flatulence","drugRate":"reported","severity":"mild"},{"effect":"Dyspepsia","drugRate":"reported","severity":"mild"},{"effect":"Elevated serum potassium levels (>5.5 mEq per liter)","drugRate":"reported","severity":"serious"},{"effect":"Skin rash","drugRate":"reported","severity":"mild"},{"effect":"Itching","drugRate":"reported","severity":"mild"},{"effect":"Dryness of mouth","drugRate":"reported","severity":"mild"},{"effect":"Pruritus","drugRate":"reported","severity":"mild"},{"effect":"Alopecia","drugRate":"reported","severity":"mild"},{"effect":"Muscle cramps","drugRate":"reported","severity":"mild"},{"effect":"Joint pain","drugRate":"reported","severity":"mild"},{"effect":"Leg ache","drugRate":"reported","severity":"mild"},{"effect":"Dizziness","drugRate":"reported","severity":"mild"},{"effect":"Paresthesia","drugRate":"reported","severity":"mild"},{"effect":"Encephalopathy","drugRate":"reported","severity":"serious"},{"effect":"Tremors","drugRate":"reported","severity":"mild"},{"effect":"Vertigo","drugRate":"reported","severity":"mild"},{"effect":"Nervousness","drugRate":"reported","severity":"mild"},{"effect":"Mental confusion","drugRate":"reported","severity":"serious"},{"effect":"Insomnia","drugRate":"reported","severity":"mild"},{"effect":"Decreased libido","drugRate":"reported","severity":"mild"},{"effect":"Depression","drugRate":"reported","severity":"serious"},{"effect":"Somnolence","drugRate":"reported","severity":"mild"},{"effect":"Cough","drugRate":"reported","severity":"mild"},{"effect":"Shortness of Breath","drugRate":"reported","severity":"serious"},{"effect":"Dyspnea","drugRate":"reported","severity":"serious"},{"effect":"Visual disturbances","drugRate":"reported","severity":"mild"},{"effect":"Nasal congestion","drugRate":"reported","severity":"mild"},{"effect":"Tinnitus","drugRate":"reported","severity":"mild"},{"effect":"Increased intraocular pressure","drugRate":"reported","severity":"serious"},{"effect":"Impotence","drugRate":"reported","severity":"mild"},{"effect":"Polyuria","drugRate":"reported","severity":"mild"},{"effect":"Dysuria","drugRate":"reported","severity":"mild"},{"effect":"Urinary frequency","drugRate":"reported","severity":"mild"},{"effect":"Bladder spasms","drugRate":"reported","severity":"mild"},{"effect":"Gynecomastia","drugRate":"reported","severity":"mild"},{"effect":"Activation of probable pre-existing peptic ulcer","drugRate":"reported","severity":"serious"},{"effect":"Aplastic anemia","drugRate":"reported","severity":"serious"},{"effect":"Neutropenia","drugRate":"reported","severity":"serious"},{"effect":"Abnormal liver function","drugRate":"reported","severity":"serious"}],"contraindications":["Acidosis","Acute pancreatitis","Anuria","Azotemia","Dehydration","Diabetes mellitus","Diabetic renal disease","Disease of liver","Gout","Hepatic coma","Hypercholesterolemia","Hyperkalemia","Hyperparathyroidism","Hyperuricemia","Hypochloremic alkalosis","Hypokalemia","Hypomagnesemia","Hyponatremia","Hypovolemia","Kidney disease","Neonatal hyperbilirubinemia","Oliguria","Secondary angle-closure glaucoma","Sympathectomy","Systemic lupus erythematosus"],"specialPopulations":{"Pregnancy":"Teratogenicity studies have been performed with combinations of amiloride hydrochloride and hydrochlorothiazide in rabbits and mice at doses up to 25 times the expected maximum daily dose for humans and have revealed no evidence of harm to the fetus. No evidence of impaired fertility in rats was apparent at dosage levels up to 25 times the expected maximum human daily dose. perinatal and postnatal study in rats showed reduction in maternal body weight gain during ","Geriatric use":"Clinical studies of amiloride hydrochloride did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or ","Paediatric use":"Safety and effectiveness in pediatric patients have not been established."}},"trials":[],"aliases":[],"company":"Padagis Us","patents":[],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$0.1862/EA","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$68","description":"AMILORIDE HCL 5 MG TABLET","retrievedDate":"2026-04-07"}],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=AMILORIDE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:34:44.476303+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:34:50.747164+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T00:34:43.121192+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=AMILORIDE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:34:51.473657+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:34:41.292157+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:34:41.292212+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T00:34:52.941517+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL945/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:34:51.928498+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA070346","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:34:41.292219+00:00"}},"allNames":"midamor","offLabel":[],"synonyms":["amiloride","amiloride hydrochloride","amiloride hydrochloride anhydrous","amiloride hydrochloride dihydrate","amiloride HCl"],"timeline":[{"date":"1981-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from PADDOCK LLC to Padagis Us"},{"date":"1981-10-05","type":"positive","source":"DrugCentral","milestone":"FDA approval (Paddock Llc)"},{"date":"2015-08-07","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 3 manufacturers approved"}],"aiSummary":"Midamor (amiloride) is a potassium-sparing diuretic, a small molecule that targets the amiloride-sensitive sodium channel, ENaC. It was originally developed by Paddock LLC and is now owned by Padagis US. Midamor is used to treat edema, hypertensive disorders, and prevent hypokalemia. It was FDA-approved in 1981 and is now off-patent with multiple generic manufacturers. As a potassium-sparing diuretic, Midamor is a key consideration for patients with potassium imbalances.","brandName":"Midamor","ecosystem":[{"indication":"Edema","otherDrugs":[{"name":"acetazolamide","slug":"acetazolamide","company":"Teva Branded Pharm"},{"name":"bumetanide","slug":"bumetanide","company":""},{"name":"chlorothiazide","slug":"chlorothiazide","company":"Oak Pharms Akorn"},{"name":"chlortalidone","slug":"chlortalidone","company":""}],"globalPrevalence":200000},{"indication":"Hypertensive disorder","otherDrugs":[{"name":"acebutolol","slug":"acebutolol","company":"Promius Pharma"},{"name":"aliskiren","slug":"aliskiren","company":"Novartis"},{"name":"amlodipine","slug":"amlodipine","company":"Pfizer"},{"name":"atenolol","slug":"atenolol","company":"Alvogen Ipco Sarl"}],"globalPrevalence":null},{"indication":"Hypokalemia Prevention","otherDrugs":[{"name":"aspartic acid","slug":"aspartic-acid","company":""},{"name":"calcium chloride","slug":"calcium-chloride","company":"Baxter Hlthcare"},{"name":"potassium acetate","slug":"potassium-acetate","company":"B Braun"},{"name":"potassium chloride","slug":"potassium-chloride","company":"Hospira"}],"globalPrevalence":null}],"mechanism":{"target":"Amiloride-sensitive sodium channel, ENaC","novelty":"Follow-on","targets":[{"gene":"SCNN1A","source":"DrugCentral","target":"Amiloride-sensitive sodium channel, ENaC","protein":"Amiloride-sensitive sodium channel subunit alpha"},{"gene":"SCNN1B","source":"DrugCentral","target":"Amiloride-sensitive sodium channel, ENaC","protein":"Amiloride-sensitive sodium channel subunit beta"},{"gene":"SCNN1G","source":"DrugCentral","target":"Amiloride-sensitive sodium channel, ENaC","protein":"Amiloride-sensitive sodium channel subunit gamma"},{"gene":"ADORA2A","source":"DrugCentral","target":"Adenosine receptor A2a","protein":"Adenosine receptor A2a"},{"gene":"MAOA","source":"DrugCentral","target":"Amine oxidase [flavin-containing] A","protein":"Amine oxidase [flavin-containing] A"},{"gene":"ASIC3","source":"DrugCentral","target":"Acid-sensing ion channel 3","protein":"Acid-sensing ion channel 3"},{"gene":"PLAU","source":"DrugCentral","target":"Urokinase-type plasminogen activator","protein":"Urokinase-type plasminogen activator"},{"gene":"ASIC1","source":"DrugCentral","target":"Acid-sensing ion channel 1","protein":"Acid-sensing ion channel 1"},{"gene":"SLC9A5","source":"DrugCentral","target":"Sodium/hydrogen exchanger 5","protein":"Sodium/hydrogen exchanger 5"},{"gene":"ASIC2","source":"DrugCentral","target":"Acid-sensing ion channel 2","protein":"Acid-sensing ion channel 2"}],"modality":"Small Molecule","drugClass":"Potassium-sparing Diuretic","explanation":"","oneSentence":"","technicalDetail":"Midamor (amiloride) acts as a competitive inhibitor of the epithelial sodium channel (ENaC), reducing sodium reabsorption in the collecting ducts of the kidneys and thereby increasing sodium excretion and reducing potassium excretion."},"commercial":{"launchDate":"1981","_launchSource":"DrugCentral (FDA 1981-10-05, PADDOCK LLC)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/158","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=AMILORIDE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=AMILORIDE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T08:40:44.034526","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:34:57.210498+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"triamterene","drugSlug":"triamterene","fdaApproval":"1964-08-10","genericCount":2,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"genericName":"amiloride","indications":{"approved":[{"name":"Edema","source":"DrugCentral","snomedId":267038008,"regulator":"FDA","eligibility":"Patients with congestive heart failure or hypertension who develop hypokalemia on the kaliuretic diuretic.","usPrevalence":null,"globalPrevalence":200000,"prevalenceMethod":"curated","prevalenceSource":"Int Arch Allergy Immunol, 2025 (PMID:39827848)"},{"name":"Hypertensive disorder","source":"DrugCentral","snomedId":38341003,"regulator":"FDA","eligibility":"Patients with hypertension who are at risk of developing hypokalemia, e.g., digitalized patients or patients with significant cardiac arrhythmias."},{"name":"Hypokalemia Prevention","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"Patients with persistent hypokalemia who require careful titration of the dose and close monitoring of serum electrolytes."}],"offLabel":[{"name":"Hypercalcemia","source":"DrugCentral","drugName":"AMILORIDE","evidenceCount":15,"evidenceLevel":"moderate"},{"name":"Nephrogenic diabetes insipidus","source":"DrugCentral","drugName":"AMILORIDE","evidenceCount":73,"evidenceLevel":"strong"},{"name":"Peripheral Edema due to Chronic Heart Failure","source":"DrugCentral","drugName":"AMILORIDE","evidenceCount":1,"evidenceLevel":"emerging"},{"name":"Pulmonary Edema due to Chronic Heart Failure","source":"DrugCentral","drugName":"AMILORIDE","evidenceCount":3,"evidenceLevel":"emerging"}],"pipeline":[]},"currentOwner":"Padagis Us","drugCategory":"mature","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"triamterene","brandName":"triamterene","genericName":"triamterene","approvalYear":"1964","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT06224673","phase":"PHASE2","title":"ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Laura Huppert, MD, BA","startDate":"2026-03-01","conditions":["HER2 Low Breast Carcinoma","Triple Negative Breast Cancer","Hormone-receptor-positive Breast Cancer","Hormone Receptor Positive Breast Carcinoma"],"enrollment":36,"completionDate":"2029-06-30"},{"nctId":"NCT03837626","phase":"PHASE2,PHASE3","title":"ENAC Blockade and Arterial Stiffness","status":"COMPLETED","sponsor":"University of Missouri-Columbia","startDate":"2019-07-15","conditions":["Overweight and Obesity","Insulin Resistance"],"enrollment":137,"completionDate":"2025-04-30"},{"nctId":"NCT04063540","phase":"PHASE2","title":"Acid-Sensing Ion Channel and Migraine Disease Proof of Concept Study on the Efficacy of Amiloride in the Prophylaxis of Migraine Aura","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2020-08-11","conditions":["Migraine With Aura"],"enrollment":40,"completionDate":"2027-12"},{"nctId":"NCT05125237","phase":"","title":"Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Amiloride vs Triamterene","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2021-10-01","conditions":["Hypertension"],"enrollment":155963,"completionDate":"2023-12-31"},{"nctId":"NCT02847338","phase":"PHASE4","title":"Comparison of Optimal Hypertension Regimens","status":"COMPLETED","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2016-11","conditions":["Hypertension"],"enrollment":940,"completionDate":"2023-10"},{"nctId":"NCT05228574","phase":"PHASE4","title":"Treatment of Vascular Stiffness in ADPKD","status":"COMPLETED","sponsor":"Erasmus Medical Center","startDate":"2022-03-11","conditions":["Autosomal Dominant Polycystic Kidney"],"enrollment":46,"completionDate":"2025-06-18"},{"nctId":"NCT05753059","phase":"PHASE1","title":"Mechanisms of Diuretic Resistance in Heart Failure, Aim 2","status":"RECRUITING","sponsor":"Yale University","startDate":"2023-08-10","conditions":["Heart Failure"],"enrollment":50,"completionDate":"2027-06"},{"nctId":"NCT01191450","phase":"PHASE3","title":"Safety and Efficacy of Chlorthalidone + Amiloride to Elderly Patients Treatment With Arterial Hypertension","status":"COMPLETED","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2011-08","conditions":["Arterial Hypertension"],"enrollment":246,"completionDate":"2013-08"},{"nctId":"NCT05044611","phase":"PHASE4","title":"AMIloride for the Treatment of Nephrogenic Diabetes Insipidus for Patients With Bipolar Disorder Treated With Lithium","status":"ACTIVE_NOT_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-01-11","conditions":["Bipolar Disorder"],"enrollment":148,"completionDate":"2026-01-11"},{"nctId":"NCT02997020","phase":"","title":"Ivacaftor for Acquired CFTR Dysfunction in Chronic Rhinosinusitis (EDSPD Protocol)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2017-05-18","conditions":["CRS"],"enrollment":30,"completionDate":"2026-04"},{"nctId":"NCT06923709","phase":"PHASE2","title":"Beneficial Effect of Amiloride on Progression of Chronic Kidney Disease","status":"RECRUITING","sponsor":"Odense University Hospital","startDate":"2024-10-10","conditions":["Chronic Kidney Disease(CKD)","Proteinuria"],"enrollment":40,"completionDate":"2025-11-01"},{"nctId":"NCT05079789","phase":"PHASE3","title":"Amiloride in Nephrotic Syndrome","status":"TERMINATED","sponsor":"University Hospital Tuebingen","startDate":"2020-06-08","conditions":["Nephrotic Syndrome","Edema","Sodium Retention"],"enrollment":20,"completionDate":"2022-11-20"},{"nctId":"NCT06209359","phase":"PHASE1","title":"Mechanisms of Diuretic Resistance in Heart Failure, Aim 3","status":"RECRUITING","sponsor":"Yale University","startDate":"2024-07-24","conditions":["Heart Failure","Diuretic Resistance"],"enrollment":50,"completionDate":"2028-03-01"},{"nctId":"NCT04331691","phase":"PHASE4","title":"Comparison of Spironolactone and Amiloride on Home Blood Pressure in Resistant Hypertension","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2020-11-16","conditions":["Resistant Hypertension"],"enrollment":118,"completionDate":"2024-05-23"},{"nctId":"NCT06416735","phase":"PHASE3","title":"Natriuretic Effect of Amiloride in Relation to the Alpha Adducin Gene (ADD-AMI) RS4961 Variant","status":"COMPLETED","sponsor":"Ospedale San Raffaele","startDate":"2018-09-28","conditions":["Hypertension Essential","Salt Excess","Genetic Hypertension"],"enrollment":40,"completionDate":"2020-07-20"},{"nctId":"NCT02525796","phase":"PHASE2,PHASE3","title":"Evaluating Alternative Medical Therapies in Primary Hyperparathyroidism","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2016-01","conditions":["Primary Hyperparathyroidism"],"enrollment":69,"completionDate":"2021-10-02"},{"nctId":"NCT04181008","phase":"EARLY_PHASE1","title":"Pharmacokinetics of Amiloride Nasal Spray in Healthy Volunteers","status":"COMPLETED","sponsor":"University of Utah","startDate":"2020-09-28","conditions":["Pharmacokinetics"],"enrollment":15,"completionDate":"2023-03-06"},{"nctId":"NCT03036748","phase":"NA","title":"Increased Activity of ENaC in Proteinuric Kidney Transplant Recipients","status":"COMPLETED","sponsor":"University of Southern Denmark","startDate":"2017-01-01","conditions":["Kidney Transplant; Complications"],"enrollment":14,"completionDate":"2021-09-01"},{"nctId":"NCT02497300","phase":"PHASE2","title":"Vascular Effects of Mineralocorticoid Receptor Antagonism in Kidney Disease","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2015-03","conditions":["Chronic Kidney Disease","Albuminuria"],"enrollment":21,"completionDate":"2021-07"},{"nctId":"NCT01210365","phase":"PHASE3","title":"Safety and Efficacy of Furosemide 40mg + Amiloride Hydrochloride 10mg to Reduct Edema","status":"TERMINATED","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2011-01-01","conditions":["Congestive Heart Failure"],"enrollment":27,"completionDate":"2013-03"},{"nctId":"NCT03174847","phase":"","title":"Prospective Study Assessing Blood Pressure and Other Outcomes Post-treatment in Patients With Primary Aldosteronism","status":"COMPLETED","sponsor":"Changi General Hospital","startDate":"2017-02-20","conditions":["Primary Aldosteronism","Primary Aldosteronism Due to Aldosterone Producing Adenoma","Primary Aldosteronism Due to Adrenal Hyperplasia (Bilateral)"],"enrollment":57,"completionDate":"2020-09-20"},{"nctId":"NCT02824718","phase":"PHASE2","title":"Recombinant Human rhPTH(1-34) VS Association Alfacalcidol/Hydrochlorothiazide in Severe Primary Hypoparathyroidism","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-06-06","conditions":["Autosomal Dominant Hypocalcemia OR Primary Hypoparathyroidism Related to Other Cause But Complicated by Hypercalciuria Under Treatment"],"enrollment":16,"completionDate":"2020-05-28"},{"nctId":"NCT03031496","phase":"PHASE1","title":"Bioequivalence Study Between GSK3542503 Hydrochlorothiazide + Amiloride Hydrochloride 50 mg: 5 mg Tablets and Reference Product in Healthy Adult Participants Under Fasting Conditions","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-03-17","conditions":["Hypertension"],"enrollment":42,"completionDate":"2017-04-10"},{"nctId":"NCT04467931","phase":"","title":"ACEI or ARB and COVID-19 Severity and Mortality in US Veterans","status":"COMPLETED","sponsor":"University of Utah","startDate":"2020-01-19","conditions":["Hypertension","COVID"],"enrollment":22213,"completionDate":"2020-12-31"},{"nctId":"NCT01202279","phase":"PHASE4","title":"Safety and Efficacy Study of Guaifenesin and Pseudoephedrine for Symptomatic Therapy to Treat Acute RTI","status":"COMPLETED","sponsor":"Reckitt Benckiser Inc.","startDate":"2009-10","conditions":["Acute Upper Respiratory Track Infection"],"enrollment":1179,"completionDate":"2010-07"},{"nctId":"NCT03170336","phase":"PHASE4","title":"A New Application of Amiloride in the Treatment of Patient With Chronic Kidney Disease In Reducing Urinary PROtein","status":"COMPLETED","sponsor":"Guangdong Provincial People's Hospital","startDate":"2018-03-01","conditions":["Chronic Kidney Diseases"],"enrollment":40,"completionDate":"2020-08-01"},{"nctId":"NCT01910259","phase":"PHASE2","title":"MS-SMART: Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial","status":"COMPLETED","sponsor":"University College, London","startDate":"2014-12-18","conditions":["Secondary Progressive Multiple Sclerosis"],"enrollment":445,"completionDate":"2018-07-04"},{"nctId":"NCT02522650","phase":"PHASE4","title":"A Crossover Pilot Study of the Effect of Amiloride on Proteinuria","status":"UNKNOWN","sponsor":"Georgetown University","startDate":"2013-07","conditions":["Proteinuria"],"enrollment":30,"completionDate":"2021-10"},{"nctId":"NCT03928145","phase":"PHASE3","title":"Efficacy of Chlorthalidone and Hydrochlorothiazide Combined With Amiloride on Blood Pressure in Primary Hypertension.","status":"UNKNOWN","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2019-11-13","conditions":["Hypertension"],"enrollment":84,"completionDate":"2021-07"},{"nctId":"NCT01246180","phase":"NA","title":"Microcirculation & ASICs","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2010-10","conditions":["Physiological Conditions"],"enrollment":20,"completionDate":"2010-12"},{"nctId":"NCT02832973","phase":"PHASE4","title":"Sequential Nephron Blockade vs. Dual Blockade Renin-angiotensin System + Bisoprolol in Resistant Arterial Hypertension","status":"COMPLETED","sponsor":"Sao Jose do Rio Preto Medical School","startDate":"2015-09","conditions":["Hypertension Resistant to Conventional Therapy"],"enrollment":72,"completionDate":"2018-03"},{"nctId":"NCT03706300","phase":"PHASE1","title":"Bioequivalence Study of Guaifenesin and Pseudoephedrine Hydrochloride Extended Release Tablets 1200/120 mg Under Fasting Conditions","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2014-12","conditions":["Healthy"],"enrollment":80,"completionDate":"2015-01"},{"nctId":"NCT01733680","phase":"EARLY_PHASE1","title":"Amiloride Hydrochloride as an Effective Treatment for ADHD","status":"TERMINATED","sponsor":"State University of New York - Upstate Medical University","startDate":"2012-09","conditions":["ADHD"],"enrollment":3,"completionDate":"2015-09"},{"nctId":"NCT02896621","phase":"PHASE3","title":"Effect of Antihypertensive Agents on Diastolic Function in Patients With Sleep Apnea","status":"COMPLETED","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2014-12-07","conditions":["Hypertension","Sleep Apnea"],"enrollment":69,"completionDate":"2017-02-14"},{"nctId":"NCT01802489","phase":"PHASE2","title":"Amiloride Clinical Trial In Optic Neuritis","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2013-02","conditions":["Optic Neuritis","Multiple Sclerosis"],"enrollment":46,"completionDate":"2015-11"},{"nctId":"NCT01804777","phase":"EARLY_PHASE1","title":"Epithelial Sodium Channel (ENaC) as a Novel Mechanism for Hypertension and Volume Expansion in Type 2 Diabetes","status":"TERMINATED","sponsor":"University of New Mexico","startDate":"2013-03","conditions":["Proteinuria","Hypertension","Type II Diabetes"],"enrollment":9,"completionDate":"2014-12"},{"nctId":"NCT02875886","phase":"PHASE4","title":"DD-study: Diet or Diuretics for Salt-sensitivity in Chronic Kidney Disease","status":"COMPLETED","sponsor":"Erasmus Medical Center","startDate":"2016-09","conditions":["Chronic Kidney Disease"],"enrollment":28,"completionDate":"2018-04"},{"nctId":"NCT00478335","phase":"NA","title":"Pharmacologic Treatment of Congenital Nephrogenic Diabetes Insipidus","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2007-05","conditions":["Nephrogenic Diabetes Insipidus"],"enrollment":4,"completionDate":"2012-10"},{"nctId":"NCT01055223","phase":"","title":"Fracture Risk With Thiazolidinediones","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-05","conditions":["Fractures, Bone","Type II Diabetes"],"enrollment":98483,"completionDate":"2010-03"},{"nctId":"NCT01896661","phase":"PHASE3","title":"Effect of Antihypertensive Agents Over Sleep Apnea","status":"COMPLETED","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2014-12","conditions":["Hypertension","Obstructive Sleep Apnea"],"enrollment":53,"completionDate":"2016-02"},{"nctId":"NCT01195805","phase":"NA","title":"The Effects of Amiloride and Spironolactone on Renophysiological and Cardiovascular Variables","status":"COMPLETED","sponsor":"Regional Hospital Holstebro","startDate":"2010-08","conditions":["Essential Hypertension"],"enrollment":25,"completionDate":"2015-08"},{"nctId":"NCT01025713","phase":"PHASE1","title":"A Phase 1 Trial to Assess the Safety, Tolerability, and Pharmacokinetics of GS 9411 in Subjects With Cystic Fibrosis (CF)","status":"WITHDRAWN","sponsor":"Gilead Sciences","startDate":"2009-12","conditions":["Cystic Fibrosis","Mucociliary Clearance"],"enrollment":0,"completionDate":"2010-04"},{"nctId":"NCT02351973","phase":"PHASE4","title":"Comparison of Single and Combination Diuretics in Low-Renin Hypertension","status":"UNKNOWN","sponsor":"University of Cambridge","startDate":"2009-11","conditions":["Hypertension"],"enrollment":423,"completionDate":"2015-08"},{"nctId":"NCT00141596","phase":"NA","title":"Extracellular Fluid in Resistant Hypertension","status":"TERMINATED","sponsor":"St George's, University of London","startDate":"2003-07","conditions":["Hypertension"],"enrollment":32,"completionDate":"2006-10"},{"nctId":"NCT01879527","phase":"PHASE2","title":"Amiloride Hydrochlorothiazide as Treatment of Acute Inflammation of the Optic Nerve","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2014-03","conditions":["Optic; Neuritis, With Demyelination"],"enrollment":78,"completionDate":"2016-04"},{"nctId":"NCT00004705","phase":"NA","title":"Study of Uridine Triphosphate (UTP) as an Aerosol Spray for Cystic Fibrosis","status":"COMPLETED","sponsor":"FDA Office of Orphan Products Development","startDate":"1996-09","conditions":["Cystic Fibrosis"],"enrollment":0,"completionDate":"1999-01"},{"nctId":"NCT00971165","phase":"PHASE3","title":"Diuretics and Angiotensin-Receptor Blocker Agents in Patients With Stage I Hypertension","status":"COMPLETED","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2010-07","conditions":["Hypertension","Cardiovascular Disease"],"enrollment":655,"completionDate":"2014-09"},{"nctId":"NCT00970931","phase":"PHASE3","title":"Hypertension Prevention in Pre-Hypertensive Individuals","status":"COMPLETED","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2010-07","conditions":["Pre-hypertension","Hypertension","Cardiovascular Disease"],"enrollment":730,"completionDate":"2014-09"},{"nctId":"NCT00709137","phase":"NA","title":"Spironolactone Versus Amiloride as an Add on Agent in Resistant Hypertension","status":"WITHDRAWN","sponsor":"VA Salt Lake City Health Care System","startDate":"2008-10","conditions":["Hypertension"],"enrollment":0,"completionDate":"2010-11"},{"nctId":"NCT02122731","phase":"PHASE4","title":"Amiloride for Resistant Hypertension","status":"COMPLETED","sponsor":"Ib Abildgaard Jacobsen","startDate":"2010-11","conditions":["Hypertension","Type 2 Diabetes Mellitus","Microalbuminuria"],"enrollment":80,"completionDate":"2012-08"},{"nctId":"NCT01635231","phase":"NA","title":"The Effect of Thiazide, Amiloride and Hypertonic Saline on Urinary Biomarkers in Healthy Subjects","status":"COMPLETED","sponsor":"Regional Hospital Holstebro","startDate":"2012-07","conditions":["Nephropathy"],"enrollment":24,"completionDate":"2013-11"},{"nctId":"NCT01146197","phase":"PHASE1,PHASE2","title":"Input of the Use of Indometacin in Gitelman Syndrome as Compared to Potassium Sparing Diuretics","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2010-02","conditions":["Gitelman Syndrome"],"enrollment":33,"completionDate":"2013-01"},{"nctId":"NCT01918488","phase":"NA","title":"Increased Activity of a Renal Salt Transporter (ENaC) in Diabetic Kidney Disease","status":"UNKNOWN","sponsor":"University of Southern Denmark","startDate":"2013-10","conditions":["Diabetic Nephropathies","Hypertension"],"enrollment":80,"completionDate":""},{"nctId":"NCT01228214","phase":"PHASE2,PHASE3","title":"Novel Treatment for Coronary Artery Disease","status":"UNKNOWN","sponsor":"University of Carabobo","startDate":"2011-03","conditions":["Coronary Artery Disease"],"enrollment":100,"completionDate":"2013-09"},{"nctId":"NCT01308983","phase":"PHASE4","title":"Study of Amiloride on Vascular Phenotypes in Young Adults With Prehypertension","status":"UNKNOWN","sponsor":"Augusta University","startDate":"2010-09","conditions":["Prehypertension"],"enrollment":32,"completionDate":""},{"nctId":"NCT01706887","phase":"NA","title":"Genetic Determinant of Blood Pressure Sensitivity to Salt Intake","status":"TERMINATED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2007-04","conditions":["Hypertension"],"enrollment":219,"completionDate":"2012-03"},{"nctId":"NCT01095133","phase":"PHASE1","title":"Do Acid Sensing Ion Channels Contribute to Heartburn?","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2010-03","conditions":["Gastroesophageal Reflux Disease","Heartburn"],"enrollment":24,"completionDate":"2011-09"},{"nctId":"NCT01011660","phase":"PHASE4","title":"Effects of Angiotensin II Receptor Blocker Compared With Diuretics in High-risk Hypertensive Patients","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences, Fuwai Hospital","startDate":"2007-10","conditions":["Essential Hypertension"],"enrollment":13542,"completionDate":"2012-12"},{"nctId":"NCT01231165","phase":"PHASE2,PHASE3","title":"Treatment of Coronary Heart Disease With Amiloride","status":"COMPLETED","sponsor":"University of Carabobo","startDate":"2009-02","conditions":["Coronary Heart Disease"],"enrollment":70,"completionDate":"2011-02"},{"nctId":"NCT01388088","phase":"PHASE4","title":"The Effect of Amiloride and Spironolactone in Patients With Hypertension","status":"COMPLETED","sponsor":"Erling Bjerregaard Pedersen","startDate":"2010-09","conditions":["Hypertension"],"enrollment":23,"completionDate":"2012-02"},{"nctId":"NCT00531908","phase":"NA","title":"Physiopathology of Sodium Retention in Acromegaly","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2007-09","conditions":["Acromegaly"],"enrollment":12,"completionDate":"2009-12"},{"nctId":"NCT00857909","phase":"PHASE1","title":"The Effect of Amiloride and Spironolactone in Healthy Persons","status":"COMPLETED","sponsor":"Regional Hospital Holstebro","startDate":"2009-01","conditions":["High Blood Pressure"],"enrollment":30,"completionDate":"2010-07"},{"nctId":"NCT00547053","phase":"PHASE1","title":"Amiloride Solution and Tobramycin Solution for Inhalation for the Eradication of Burkholderia Dolosa in Patients With Cystic Fibrosis","status":"COMPLETED","sponsor":"Boston Children's Hospital","startDate":"2006-12","conditions":["Cystic Fibrosis"],"enrollment":25,"completionDate":"2011-01"},{"nctId":"NCT00285805","phase":"NA","title":"The Influence of Rosiglitazone on the Diuretic Effect of Furosemide and Amiloride","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2006-02","conditions":["Insulin Resistance"],"enrollment":13,"completionDate":"2006-11"},{"nctId":"NCT00999531","phase":"PHASE1","title":"A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Trial of GS-9411 in Healthy Volunteers","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2009-10","conditions":["Cystic Fibrosis","Mucociliary Clearance","Airway Hydration"],"enrollment":24,"completionDate":"2010-03"},{"nctId":"NCT00800579","phase":"PHASE1","title":"Trial to Assess the Safety, Tolerability and Pharmacokinetics of GS-9411 in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2008-11","conditions":["Cystic Fibrosis"],"enrollment":12,"completionDate":"2009-02"},{"nctId":"NCT00951522","phase":"PHASE1","title":"A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of GS-9411 in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2009-09","conditions":["Cystic Fibrosis","Mucociliary Clearance","Airway Hydration"],"enrollment":15,"completionDate":"2009-09"},{"nctId":"NCT00424801","phase":"NA","title":"Effects of Intensive Long-Term Vasodilation in Hypertensive Patients With Microvascular Angina Pectoris","status":"TERMINATED","sponsor":"University of Aarhus","startDate":"2007-01","conditions":["Microvascular Angina","Hypertension"],"enrollment":10,"completionDate":"2008-12"},{"nctId":"NCT00684489","phase":"NA","title":"Renin-Guided Therapeutics in the Management of Untreated, Uncontrolled, or Complicated Hypertension","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2003-09","conditions":["Hypertension"],"enrollment":52,"completionDate":"2005-09"},{"nctId":"NCT00441246","phase":"PHASE4","title":"Phase 4 Study - Mucinex D as Adjunct Therapy","status":"COMPLETED","sponsor":"Adams Respiratory Therapeutics","startDate":"2007-02","conditions":["Acute Respiratory Infection","Bronchitis","Rhinosinusitis"],"enrollment":600,"completionDate":"2007-07"},{"nctId":"NCT00429897","phase":"NA","title":"Double Blind Crossover Comparison of Diuretics in the Young","status":"UNKNOWN","sponsor":"University of Cambridge","startDate":"2006-08","conditions":["Low-Renin Hypertension"],"enrollment":30,"completionDate":"2007-07"},{"nctId":"NCT00394394","phase":"PHASE2","title":"Antihypertensive Effectiveness of the Associations of Hydrochlorothiazide and Amiloride and Hydrochlorothiazide and Enalapril","status":"COMPLETED","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2005-02","conditions":["Hypertension"],"enrollment":0,"completionDate":""},{"nctId":"NCT00274391","phase":"PHASE2","title":"Efficacy of Amiloride and Hypertonic Saline in Cystic Fibrosis","status":"COMPLETED","sponsor":"University of North Carolina","startDate":"2001-07","conditions":["Cystic Fibrosis"],"enrollment":24,"completionDate":"2004-04"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral","formulation":"Tablet","formulations":[{"form":"TABLET","route":"ORAL","productName":"Amiloride Hydrochloride"},{"form":"TABLET","route":"ORAL","productName":"Amiloride Hydrochloride and Hydrochlorothiazide"},{"form":"TABLET","route":"ORAL","productName":"amiloride hydrochloride"},{"form":"TABLET","route":"ORAL","productName":"AMILORIDE HYDROCHLORIDE"},{"form":"TABLET","route":"ORAL","productName":"amiloride hydrocloride"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000147699","MMSL":"2658","NDDF":"002316","UNII":"7DZO8EB0Z3","VUID":"4019603","CHEBI":"CHEBI:2639","VANDF":"4017935","INN_ID":"2352","RXNORM":"1298837","UMLSCUI":"C0002502","chemblId":"CHEMBL945","ChEMBL_ID":"CHEMBL945","KEGG_DRUG":"D00649","DRUGBANK_ID":"DB00594","PDB_CHEM_ID":" AMR","PUBCHEM_CID":"16231","SNOMEDCT_US":"1268944002","IUPHAR_LIGAND_ID":"2421","SECONDARY_CAS_RN":"17440-83-4","MESH_DESCRIPTOR_UI":"D000584"},"formularyStatus":[],"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"1981-","companyName":"Paddock Llc","relationship":"Original Developer"},{"period":"present","companyName":"Padagis Us","relationship":"Current Owner"}],"pharmacokinetics":{"source":"DrugCentral","bioavailability":"50%"},"publicationCount":10835,"therapeuticAreas":["Immunology"],"atcClassification":{"source":"DrugCentral","atcCode":"C03DB01","allCodes":["C03DB01"]},"biosimilarFilings":[],"originalDeveloper":"Paddock Llc","recentPublications":[],"companionDiagnostics":[],"genericManufacturers":3,"_genericFilersChecked":true,"genericManufacturerList":["Chartwell Rx","Ph Health","Sigmapharm Labs Llc"],"status":"approved","companyName":"Padagis Us","companyId":"padagis-us","modality":"Small molecule","firstApprovalDate":"1981","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1986-01-22T00:00:00.000Z","mah":"PH HEALTH","brand_name_local":null,"application_number":"ANDA070346"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1991-05-14T00:00:00.000Z","mah":"PADAGIS US","brand_name_local":null,"application_number":"NDA018200"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1993-04-14T00:00:00.000Z","mah":"BARR","brand_name_local":null,"application_number":"ANDA071111"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2009-01-30T00:00:00.000Z","mah":"SIGMAPHARM LABS LLC","brand_name_local":null,"application_number":"ANDA079133"},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":3,"withResults":2},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:34:57.210498+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}